The Federal Trade Commission is scheduled to vote today on whether or not to reverse course on prior statements that opposed mandatory PBM transparency and disclosure requirements. The vote, if successful, will effectively remove a major line of defense for PBMs that promote one-sided business relationships, stifle competition and reduce patient choice. NCPA’s General Counsel, Matt Seiler, submitted oral comments to the commissioners encouraging them to vote yes on the matter. It comes on the heels of last month’s roundtable discussion at Eric’s RX Shoppe in Horsham, Pa., with area pharmacists and FTC Commissioner Alvaro Bedoya, which focused on access issues for patients whose local pharmacies have closed, take-it-or-leave-it contracts, lack of transparency, patient-steering, and the anticipated DIR hangover in 2024. Learn more about the vote’s outcome in tomorrow’s Executive Update (a member-only benefit delivered to your inbox) and stay tuned to qAM for the FTC’s new language around mandatory PBM transparency and disclosure requirements.
NCPA
